FDA Clears First-Of-A-Kind Breast Cancer Recurrence Test
This article was originally published in The Gray Sheet
Executive Summary
Dutch firm Agendia's MammaPrint test for predicting breast cancer recurrence set regulatory precedent Feb. 6 when it received 510(k) clearance